Open Nav

GenomeMe Lab Inc.

  • Mohammad Tabesh, GenomeMe

Partnership / Investment

  • Date:Thursday, October 18
  • Time:10:00 AM - 10:15 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:GenomeMe is an antibody developer and manufacturer with a focus on Precision Diagnostics. GenomeMe's product lines include IHC grade antibodies used as companion diagnostics to detect, characterize, and inform treatment options for cancer patients. GenomeMe is the only company in the world with complete A-Z expertise in antibody development and commercialization. With over 73 hybridoma clones established and commercialized in the past 12 months for diagnostic applications, GenomeMe is fast becoming an industry leader. Our current portfolio includes important diagnostic markers such p16, PD-L1, Her2, IDH1 R132H, and BRAF V600E as well as immunotherapeutic targets such as PD-1, GITR, RORgT, OX-40, OX-40 Ligand, TIM3, CTLA-4, etc. GenomeMe is currently further characterizing its clones for therapeutic applications. Our initial cell based assays have identified promising candidates for PD-L1 and CTLA-4 based on larger induced cytokine release compared to the FDA approved PD-1 drug.
  • Company
  • Company HQ City:Richmond
  • Company HQ Country:Canada
  • Company HQ State:British Columbia
  • Year Founded:2015
  • Main Therapeutic Focus:Diagnostics
  • Lead Product in Development :Monoclonal Antibodies for Companion Diagnostics and Therapeutics
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :73
  • Total Amount Raised to Date, In All Rounds:2000000
Mohammad Tabesh